Patents Assigned to Cyteir Therapeutics, Inc.
  • RAD51 inhibitors
    Patent number: 11932636
    Abstract: This application is directed to inhibitors of RAD51 represented by the following structural formula, and methods for their use, such as to treat cancer, autoimmune diseases, immune deficiencies, or neurodegenerative diseases.
    Type: Grant
    Filed: December 16, 2021
    Date of Patent: March 19, 2024
    Assignee: Cyteir Therapeutics, Inc.
    Inventors: Jean-Marc Lapierre, Casey Cameron McComas, Joseph Vacca
  • Combinations of RAD51 and PARP inhibitors
    Patent number: 11607404
    Abstract: This application is directed to inhibitors of RAD51 represented by the following structural formula: in combination with a PARP inhibitor, and methods for their use, such as to treat cancer, autoimmune diseases, immune deficiencies, or neurodegenerative diseases.
    Type: Grant
    Filed: March 25, 2020
    Date of Patent: March 21, 2023
    Assignee: Cyteir Therapeutics, Inc.
    Inventors: Alfredo C. Castro, Melinda Day, Tyler Maclay, Casey Cameron McComas, Kevin Mills, Joseph Vacca
  • RAD51 inhibitors
    Patent number: 11291655
    Abstract: This application is directed to inhibitors of RAD51, and methods for their use, such as to treat or prevent conditions involving mitochondrial defects.
    Type: Grant
    Filed: July 11, 2018
    Date of Patent: April 5, 2022
    Assignee: Cyteir Therapeutics, Inc.
    Inventors: Alfredo C. Castro, Casey Cameron McComas, Joseph Vacca
  • RAD51 inhibitors
    Patent number: 11247988
    Abstract: This application is directed to inhibitors of RAD51 represented by the following structural formula, and methods for their use, such as to treat cancer, autoimmune diseases, immune deficiencies, or neurodegenerative diseases.
    Type: Grant
    Filed: March 12, 2020
    Date of Patent: February 15, 2022
    Assignee: Cyteir Therapeutics, Inc.
    Inventors: Jean-Marc Lapierre, Casey Cameron McComas, Joseph Vacca
  • RAD51 inhibitors
    Patent number: 11084812
    Abstract: This application is directed to inhibitors of RAD51 represented by the following structural formula, and methods for their use, such as to treat cancer, autoimmune diseases, immune deficiencies, or neurodegenerative diseases.
    Type: Grant
    Filed: January 6, 2020
    Date of Patent: August 10, 2021
    Assignee: Cyteir Therapeutics, Inc.
    Inventors: Alfredo C. Castro, Casey Cameron McComas, Joseph Vacca, Tyler Maclay
  • RAD51 inhibitors
    Patent number: 10590122
    Abstract: This application is directed to inhibitors of RAD51 represented by the following structural formula, and methods for their use, such as to treat cancer, autoimmune diseases, immune deficiencies, or neurodegenerative diseases.
    Type: Grant
    Filed: September 11, 2018
    Date of Patent: March 17, 2020
    Assignee: Cyteir Therapeutics, Inc.
    Inventors: Alfredo C. Castro, Casey Cameron McComas, Joseph Vacca, Tyler Maclay
  • RAD51 inhibitors
    Patent number: 10336746
    Abstract: This application is directed to inhibitors of RAD51 represented by the following structural formula, and methods for their use, such as to treat cancer, autoimmune diseases, immune deficiencies, or neurodegenerative diseases.
    Type: Grant
    Filed: December 31, 2018
    Date of Patent: July 2, 2019
    Assignee: Cyteir Therapeutics, Inc.
    Inventors: Alfredo C. Castro, Casey Cameron McComas, Joseph Vacca, Tyler Maclay